UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 33

Sortiert nach

Reprogramming T-cell metabolism to enhance adoptive cell therapies

International immunology, 2024-04, Vol.36 (6), p.261-278

2024

Volltextzugriff (PDF)

The Role of Adjuvant Radiotherapy for the Treatment of Resected High-Risk Stage III Cutaneous Melanoma in the Era of Modern Systemic Therapies

Cancers, 2023-12, Vol.15 (24), p.5867

2023

Volltextzugriff (PDF)

Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors

Oncoimmunology, 2024, Vol.13 (1), p.2349347-2349347

2024

Volltextzugriff (PDF)

Immune Checkpoint Inhibitors in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience from a Canadian Comprehensive Cancer Centre

Cancers, 2023-08, Vol.15 (17), p.4312

2023

Volltextzugriff (PDF)

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy

Journal for immunotherapy of cancer, 2021-01, Vol.9 (1), p.e001642

2021

Volltextzugriff (PDF)

Analysis of the Circulating Metabolome of Patients with Cutaneous, Mucosal and Uveal Melanoma Reveals Distinct Metabolic Profiles with Implications for Response to Immunotherapy

Cancers, 2023-07, Vol.15 (14), p.3708

2023

Volltextzugriff (PDF)

CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus

Cancers, 2021-12, Vol.14 (1), p.89

2021

Volltextzugriff (PDF)

Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors

Cancers, 2021-07, Vol.13 (14), p.3640

2021

Volltextzugriff (PDF)

Immune checkpoint inhibitors in cancer immunotherapy

Canadian Medical Association journal (CMAJ), 2020-06, Vol.192 (24), p.E651

2020

Volltextzugriff (PDF)

Coenzyme A fuels T cell anti-tumor immunity

Cell metabolism, 2021-12, Vol.33 (12), p.2415-2427.e6

2021

Volltextzugriff (PDF)

Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2

Cancer Immunology, Immunotherapy, 2019-05, Vol.68 (5), p.773-785

2019

Volltextzugriff (PDF)

Activation of Peroxisome Proliferator-Activated Receptors α and δ Synergizes with Inflammatory Signals to Enhance Adoptive Cell Therapy

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (3), p.445-451

2019

Volltextzugriff (PDF)

DNA damage- and stress-induced apoptosis occurs independently of PIDD

Apoptosis (London), 2009-09, Vol.14 (9), p.1039-1049

2009

Volltextzugriff (PDF)

RIP2 contributes to Nod signaling but is not essential for T cell proliferation, T helper differentiation or TLR responses

European journal of immunology, 2008, Vol.38 (1), p.64-72

2008

Volltextzugriff (PDF)

Presumed complement-mediated, checkpoint inhibitor-induced, thrombotic microangiopathy in a patient with metastatic melanoma

BMJ case reports, 2021-07, Vol.14 (7), p.e242075

2021

Volltextzugriff (PDF)

IL6 Induces an IL22 + CD8 + T-cell Subset with Potent Antitumor Function

Cancer immunology research, 2020-03, Vol.8 (3), p.321-333

2020

Volltextzugriff (PDF)

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition

Journal for immunotherapy of cancer, 2021-01, Vol.9 (1), p.e001931

2021

Volltextzugriff (PDF)

Glycogen Synthase Kinase-3 Modulates Cbl-b and Constrains T Cell Activation

The Journal of immunology (1950), 2017-12, Vol.199 (12), p.4056-4065

2017

Volltextzugriff (PDF)

Ex vivo activation of the GCN2 pathway metabolically reprograms T cells, leading to enhanced adoptive cell therapy

Cell reports. Medicine, 2024-03, Vol.5 (3), p.101465-101465, Article 101465

2024

Volltextzugriff (PDF)

ARIH2 is essential for embryogenesis, and its hematopoietic deficiency causes lethal activation of the immune system

Nature immunology, 2013-01, Vol.14 (1), p.27

2013

Volltextzugriff (PDF)

Marked Induction of the IAP Family Antiapoptotic Proteins Survivin and XIAP by VEGF in Vascular Endothelial Cells

Biochemical and biophysical research communications, 1999-11, Vol.264 (3), p.781-788

1999

Volltextzugriff (PDF)

Turnaround Times in Melanoma BRAF Testing and the Impact on the Initiation of Systemic Therapy at a Single Tertiary Care Cancer Center

JCO oncology practice, 2022-05, Vol.18 (5), p.e642-e647

2022

Volltextzugriff (PDF)

The sound of silence: modulating anergy in T lymphocytes

Current opinion in immunology, 2007-12, Vol.19 (6), p.658-664

2007

Volltextzugriff (PDF)

Weak agonist self‐peptides promote selection and tuning of virus‐specific T cells

European journal of immunology, 2003-03, Vol.33 (3), p.685-696

2003

Volltextzugriff (PDF)

Targeting T cell activation in immuno-oncology

Current oncology (Toronto), 2020-04, Vol.27 (Suppl 2), p.S98-105

2020

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(33)

Sprache

Englisch
(33)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Reprogramming T-cell metabolism to enhance adoptive cell therapies

The Role of Adjuvant Radiotherapy for the Treatment of Resected High-Risk Stage III Cutaneous Melanoma in the Era of Modern Systemic Therapies

Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors

Immune Checkpoint Inhibitors in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience from a Canadian Comprehensive Cancer Centre

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy

Analysis of the Circulating Metabolome of Patients with Cutaneous, Mucosal and Uveal Melanoma Reveals Distinct Metabolic Profiles with Implications for Response to Immunotherapy

CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus

Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors

Immune checkpoint inhibitors in cancer immunotherapy

Coenzyme A fuels T cell anti-tumor immunity

Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2

Activation of Peroxisome Proliferator-Activated Receptors α and δ Synergizes with Inflammatory Signals to Enhance Adoptive Cell Therapy

DNA damage- and stress-induced apoptosis occurs independently of PIDD

RIP2 contributes to Nod signaling but is not essential for T cell proliferation, T helper differentiation or TLR responses

Presumed complement-mediated, checkpoint inhibitor-induced, thrombotic microangiopathy in a patient with metastatic melanoma

IL6 Induces an IL22 + CD8 + T-cell Subset with Potent Antitumor Function

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition

Glycogen Synthase Kinase-3 Modulates Cbl-b and Constrains T Cell Activation

Ex vivo activation of the GCN2 pathway metabolically reprograms T cells, leading to enhanced adoptive cell therapy

ARIH2 is essential for embryogenesis, and its hematopoietic deficiency causes lethal activation of the immune system

Marked Induction of the IAP Family Antiapoptotic Proteins Survivin and XIAP by VEGF in Vascular Endothelial Cells

Turnaround Times in Melanoma BRAF Testing and the Impact on the Initiation of Systemic Therapy at a Single Tertiary Care Cancer Center

The sound of silence: modulating anergy in T lymphocytes

Weak agonist self‐peptides promote selection and tuning of virus‐specific T cells

Targeting T cell activation in immuno-oncology

Suchergebnisse filtern